BACKGROUND: The influence of patient age and sex on delivery of guideline-recommended heart failure (HF) therapies in contemporary outpatient settings has not been well studied. The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) is a prospective cohort study designed to characterize current management of outpatients with chronic HF and left ventricular ejection fraction < or =35%. METHODS: Baseline data for eligible patients with systolic HF in a national registry of 167 US outpatient cardiology practices were collected by trained chart abstractors. Data were stratified and analyzed as male/female and by age tertiles with generalized estimating equation models constructed for 7 care measures. RESULTS: A total of 15,381 patients were enrolled, with 8,770 (71.1%) of these male. Median age of female patients was 72.0 and 70.0 for males. Use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone inhibitors, and cardiac resynchronization therapy was not significantly different between male and female patients, but rates for implantable cardioverter defibrillators, anticoagulation therapy for atrial fibrillation, and HF education were significantly lower for females. After adjusting for patient and practice characteristics, 3 of 7 measures significantly differed by patient sex, and 6 of 7 measures by age. Older patients, particularly older women, were significantly less likely to receive guideline-indicated HF therapies. CONCLUSIONS: Patient age and sex were independently associated with reduced rates of some, but not all, HF therapies in outpatient cardiology practices. Older women are especially at risk. Further research is needed to understand the causes and consequences of these age- and sex-related differences in care.
BACKGROUND: The influence of patient age and sex on delivery of guideline-recommended heart failure (HF) therapies in contemporary outpatient settings has not been well studied. The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) is a prospective cohort study designed to characterize current management of outpatients with chronic HF and left ventricular ejection fraction < or =35%. METHODS: Baseline data for eligible patients with systolic HF in a national registry of 167 US outpatient cardiology practices were collected by trained chart abstractors. Data were stratified and analyzed as male/female and by age tertiles with generalized estimating equation models constructed for 7 care measures. RESULTS: A total of 15,381 patients were enrolled, with 8,770 (71.1%) of these male. Median age of female patients was 72.0 and 70.0 for males. Use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone inhibitors, and cardiac resynchronization therapy was not significantly different between male and female patients, but rates for implantable cardioverter defibrillators, anticoagulation therapy for atrial fibrillation, and HF education were significantly lower for females. After adjusting for patient and practice characteristics, 3 of 7 measures significantly differed by patient sex, and 6 of 7 measures by age. Older patients, particularly older women, were significantly less likely to receive guideline-indicated HF therapies. CONCLUSIONS:Patient age and sex were independently associated with reduced rates of some, but not all, HF therapies in outpatient cardiology practices. Older women are especially at risk. Further research is needed to understand the causes and consequences of these age- and sex-related differences in care.
Authors: Paul L Hess; Maria V Grau-Sepulveda; Adrian F Hernandez; Eric D Peterson; Deepak L Bhatt; Lee H Schwamm; Clyde W Yancy; Gregg C Fonarow; Sana M Al-Khatib Journal: J Cardiovasc Electrophysiol Date: 2013-02-25
Authors: Saul Blecker; Yiyi Zhang; Daniel E Ford; Eliseo Guallar; Susan Dosreis; Donald M Steinwachs; Lisa B Dixon; Gail L Daumit Journal: Gen Hosp Psychiatry Date: 2010-03-16 Impact factor: 3.238
Authors: Jonathan G Howlett; Robert S McKelvie; Jeannine Costigan; Anique Ducharme; Estrellita Estrella-Holder; Justin A Ezekowitz; Nadia Giannetti; Haissam Haddad; George A Heckman; Anthony M Herd; Debra Isaac; Simon Kouz; Kori Leblanc; Peter Liu; Elizabeth Mann; Gordon W Moe; Eileen O'Meara; Miroslav Rajda; Samuel Siu; Paul Stolee; Elizabeth Swiggum; Shelley Zeiroth Journal: Can J Cardiol Date: 2010-04 Impact factor: 5.223
Authors: Robbert Zusterzeel; Kimberly A Selzman; William E Sanders; Kathryn M O'Callaghan; Daniel A Caños; Kevin Vernooy; Frits W Prinzen; Anton P M Gorgels; David G Strauss Journal: J Cardiovasc Transl Res Date: 2015-12-10 Impact factor: 4.132
Authors: Ken Lee Chin; Marina Skiba; Andrew Tonkin; Christopher M Reid; Danny Liew; Henry Krum; Ingrid Hopper Journal: Heart Fail Rev Date: 2016-11 Impact factor: 4.214
Authors: W von Scheidt; C Zugck; M Pauschinger; R Hambrecht; O Bruder; A Hartmann; M Rauchhaus; R Zahn; J Brachmann; U Tebbe; T Neumann; R H Strasser; M Böhm; S Störk; M Hochadel; P Heidemann; J Senges Journal: Clin Res Cardiol Date: 2014-07-23 Impact factor: 5.460
Authors: David D McManus; Jane S Saczynski; Darleen Lessard; Menhel Kinno; Rahul Pidikiti; Nada Esa; Josephine Harrington; Robert J Goldberg Journal: Am J Cardiol Date: 2013-05-15 Impact factor: 2.778
Authors: Mona Fiuzat; Daniel Wojdyla; Dalane Kitzman; Jerome Fleg; Steven J Keteyian; William E Kraus; Ileana L Piña; David Whellan; Christopher M O'Connor Journal: J Am Coll Cardiol Date: 2012-05-02 Impact factor: 24.094